Related Experiment Video
Updated: Oct 13, 2025
In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
Published on: August 20, 2016
Demethoxycurcumin inhibits the cell migration and MMP-2 expression in human retinal pigment epithelial cells by
Kai Wang1, Pei-Ni Chen2, Hsiang-Wen Chien1
1Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan; Departments of Ophthalmology, Sijhih Cathay General Hospital, New Taipei City, Taiwan; School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
Abstract:
Proliferative vitreoretinopathy (PVR) involves retinal pigment epithelium (RPE) cell proliferation and migration and leads to tractional retinal detachment. Demethoxycurcumin (DMC), a curcuminoid, has anti-inflammatory and anti-tumour properties. However, whether DMC affects the migration of RPE cells and the molecular mechanism of human PVR remains unclear. The aim of the current study was to investigate the effects of DMC on the inhibition of migration and proteinase expression of human ARPE-19 cells. Herein, we provided molecular evidence associated with PVR prevention through DMC by inhibiting ARPE-19 cell migration. We performed gelatin zymography, Western blot and RT-PCR and respectively found that DMC is sufficient to reduce matrix metalloproteinase-2 (MMP-2) activity, protein level and mRNA expression. DMC suppressed the nuclear levels of transcriptional factors specificity protein 1 and c-Fos, which are involved in the modulation of the transcriptional activation of the MMP-2 gene. DMC also inhibited STAT-3 phosphorylation in ARPE-19 cells. Selective STAT-3 induction by a STAT-3 activator, colivelin, reverted MMP activity and protein expression and cell migration, which were reduced in response to DMC. The results proved the inhibitory effect of DMC on RPE cell migration and MMP-2 expression by the down-regulation of the STAT-3 signalling pathway.
Insights
Demethoxycurcumin (DMC) inhibits retinal pigment epithelium (RPE) cell migration, a key factor in proliferative vitreoretinopathy (PVR). DMC reduces matrix metalloproteinase-2 (MMP-2) expression by down-regulating the STAT-3 signaling pathway, offering potential for PVR prevention.
Area of Science:
- Ophthalmology
- Cell Biology
- Molecular Medicine
Background:
- Proliferative vitreoretinopathy (PVR) is characterized by retinal pigment epithelium (RPE) cell proliferation and migration, leading to tractional retinal detachment.
- Demethoxycurcumin (DMC), a curcuminoid, exhibits anti-inflammatory and anti-tumor properties, but its effect on RPE cell migration and PVR mechanisms is not fully understood.
Purpose of the Study:
- To investigate the inhibitory effects of DMC on human ARPE-19 cell migration and proteinase expression.
- To elucidate the molecular mechanisms underlying DMC's action in the context of PVR.
Main Methods:
- Gelatin zymography, Western blot, and RT-PCR were employed to assess matrix metalloproteinase-2 (MMP-2) activity, protein levels, and mRNA expression.
- Nuclear levels of transcription factors (Sp1, c-Fos) and STAT-3 phosphorylation were analyzed.
- The role of the STAT-3 pathway was confirmed using a STAT-3 activator, colivelin.
Main Results:
- DMC significantly reduced MMP-2 activity, protein levels, and mRNA expression in ARPE-19 cells.
- DMC suppressed the nuclear translocation of Sp1 and c-Fos and inhibited STAT-3 phosphorylation.
- STAT-3 activation by colivelin reversed the inhibitory effects of DMC on MMP activity, protein expression, and cell migration.
Conclusions:
- DMC effectively inhibits RPE cell migration and MMP-2 expression.
- The mechanism involves the down-regulation of the STAT-3 signaling pathway.
- DMC demonstrates potential as a therapeutic agent for preventing PVR.
